Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Breast Cancer 11/25/2008 - (DGNews)
    Mammogram Most Effective 12 Months After Radiation Treatment - (DGNews)
    Mammograms May Detect Some Cancers That Would Have Otherwise Regressed - (DGNews)
    Type of Breast Reconstruction Impacts Radiation Therapy Outcomes - (DGNews)

    News archive

     Recent webcasts/CME - Breast Cancer

    Webcasts/CME archive

     Recent cases - Breast Cancer
      Mucinous Breast Carcinoma Presenting as Paget's Disease of the Nipple in a Man: A Case Report
      Presentation and Course of Brain Metastases from Breast Cancer in a Paranoid-Schizophrenic Patient: A Case Report
      Granular Cell Tumour of the Pectoral Muscle Mimicking Breast Cancer
      Primary Osteosarcoma of the Breast: Case Report
      A Case of Matrix-Producing Carcinoma of the Breast

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Oral Ibandronate Offers Palliative Benefits to Patients Who Progress on First-Line Bisphosphonate Therapy: Presented at SABCS

      By Charlene Laino

      SAN ANTONIO, TX -- December 19, 2006 -- Second-line therapy with oral ibandronate can provide significant palliative benefits to patients with metastatic breast cancer who have bony progression or a skeletal-related event on first-line bisphosphonate therapy, a prospective study suggests.

      Mark Clemons, MD, head, Breast Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada, presented the results here on December 15th at the 29th Annual San Antonio Breast Cancer Symposium (SABCS).

      Dr. Clemons said that in Canada, the most commonly used bisphosphonates are oral clodronate and intravenous pamidronate, with therapy typically maintained until end of life in 90% of patients. But a substantial number of patients with metastatic breast cancer have bony progression or develop a skeletal-related event despite the therapy. For such women, the optimal management strategy is not known, he said.

      The new study evaluated the impact of 12 weeks of second-line treatment with 50 mg/day of oral ibandronate on pain control and bone turnover in 30 patients with metastatic breast cancer. Of the total, 7 patients had been on clodronate and 23 on pamidronate. Fifteen women had progressive bone disease and 15 had skeletal-related events. Their median age was 57 years.

      By week 12, patients experienced a statistically significant improvement in pain control on the Brief Pain Inventory (P = .013), Dr. Clemons reported. Of 26 evaluable patients, 46.2% achieved a palliative response, defined as a reduction of at least 2 points from their worst pain score.

      There was also a statistically significant reduction in bone turnover, reflected by a median 35% reduction in urinary N-telopeptide levels relative to baseline (P < .01), he said.

      Of the 23 patients who initially received intravenous pamidronate, 87.0% said they preferred oral therapy.

      "In clinical practice, most patients with bony progression or skeletal-related events are maintained on the same bisphosphonate with any supportive evidence," Dr. Clemons said. "If these findings are confirmed through randomized trials, clinicians can start breaking away from this paradigm."


      [Presentation title: Oral Ibandronate Provides Significant Palliative Benefit in Metastatic Breast Cancer Patients Who Have Experienced Bony Progression or a Skeletal Related Event (SRE) Despite First-Line Bisphosphonate Therapy. Abstract 3147]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send